Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Probiotics may tame nausea from popular Weight-Loss shots

NCT ID NCT07213323

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study tests whether taking probiotics can reduce digestive side effects like nausea and diarrhea in people starting weight-loss drugs such as semaglutide or tirzepatide. Fifty adults with obesity will take either a probiotic capsule or a placebo daily for 26 weeks. The goal is to see if probiotics help maintain a better quality of life during the first few months of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotics (dietary supplement)
What this could lead to
If it works, this could offer a simple way to reduce nausea and stomach issues from popular weight-loss drugs, helping people stay on treatment longer.
What could go wrong
This is a small, early-stage trial with only 50 people. Probiotics may not help everyone, and the study hasn't started yet, so results are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient who is going to start a GLP-1 RA (semaglutide or tirzepatide) for weight management * Men or Women * BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 associated with one or more co-morbidities (arterial hypertension, sleep apnea, dyslipidemia, arthritis) * Between 18 and 75 years old * In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g. transportation to and from trial site, ability to understand and fill the self-rating scales, drug compliance, availability to attend to the scheduled visits, etc…). * Patient who agrees to be included in the study and who signs the informed consent form * Female participants of childbearing potential must agree to use effective contraception * Patient affiliated to a healthcare insurance plan Exclusion Criteria: Criteria relating to the study population: * Patients under 18 years old * Patient with contraindication to semaglutide or tirzepatide according to the Summary of Product Characteristics (SPC). * Patients scheduled for bariatric surgery during the study period * Patients who have had bariatric surgery in the last 12 months * Patient with a current diagnosis of diabetes. * Patients with a current diagnosis of liver cirrhosis, short bowel syndrome or inflammatory bowel disease (IBD). * Patients with severely weakened immune system. * Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine, or other systemic disease. Product criteria: Patient with known allergy to the product of the study Prohibited treatments : Current associated treatments or used in the last 30 days: GLP-1 RA, Anti-obesity drugs (AOD), Corticosteroids, Atypical neuroleptics, Antibiotics, Probiotics, Prebiotics Regulatory criteria : * Persons deprived of their liberty by a judicial or administrative decision * Persons under psychiatric care * Persons admitted to a health or social institution for purposes other than research * Adults subject to a legal protection measure (guardianship, curatorship) * Persons not affiliated to a social security scheme or beneficiaries of a similar scheme * Subjects participating in other interventional research with an exclusion period still in progress at pre-inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digestive disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Digestive System Diseases digestive system disorder Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Lyon Sud

    RECRUITING

    Pierre-Bénite, 69495, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.